PharmAla Biotech Ready to Supply MDMA to U.S. Market Following Executive Order

Key Facts

PharmAla Biotech has confirmed its readiness to supply MDMA to the U.S. market through the Expanded Access pathway, following a Presidential Executive Order designed to fast-track psychedelic drug approvals. Alongside this strategic move, the company released its Q2 financial and operational results for the period ending February 28, 2026, which included the granting of stock options as part of its recent updates. PharmAla also plans to initiate human dosing this year for its proprietary, next-generation patented MDMA product engineered for enhanced safety. Investors are closely monitoring the company, traded under tickers CSE: MDMA and OTC: MDXXF, as it leverages new regulatory flexibilities in the United States. This development provides incremental bullish momentum, underpinned by clear supply readiness, clinical milestones, and fiscal transparency.

Version History